Subscribe to Newsletter

James N. Thomas

The Power List 2021 – Biopharmaceuticals

EVP, Global Head of Biotherapeutics and President of US Operations at Just - Evotec Biologics

Over the course of his career, Thomas has contributed to the advancement of many important therapeutics including Activase, Vectibix, Enbrel, Prolia/Xgeva, and Repatha, as well as numerous biosimilar programs. Thomas is passionate about creating and using innovative technologies to meet the needs of patients. In 2014, he co-founded and became CEO of Just Biotherapeutics, with a focus on expanding global access to biologics, and is now continuing this journey at Just - Evotec Biologics.

“How can we accelerate drug development projects of the future? Through systematic, vertically integrated modality platforms bound together and defined through a common data pool. Acceleration requires prediction, and the machine learning and AI tools that are available or emerging will be capable of doing this if the right data are captured and registered. A data-rich systems approach should go as far back into the discovery process as possible to capture improvements to speed, cost, quality, number of clinical experiments and ultimately clinical success rates. This approach will not only accelerate drug development, but reduce R&D costs and, ultimately, improve patient access.”

Part of the Power List 2021

Find out more

Welcome to our annual celebration of the great and inspirational minds that contribute to the development and manufacture of new medicinal products

Go to The Power List 2021

Register to The Medicine Maker

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Medicine Maker magazine